Fig 1.
Study design.
Fig 2.
Mutation distribution in plasma samples of 121 NSCLC patients at diagnosis.
Fig 3.
Median allele frequency of mutations detected in tissue and plasma grouped based on their concordance among the two materials.
Fig 4.
Comparison of the mutation distribution in plasma and tissue of 36 patients with newly diagnosed NSCLC.
Table 1.
Sensitivity, specificity, PPV (Positive Predictive Value) and concordance for mutations detected in paired plasma and tissue biopsy analysis.
Fig 5.
EGFR mutation distribution in ctDNA of 50 patients with an EGFR mutation at diagnosis that have relapsed following TKI treatment.
A. Analysis by cobas B. Analysis by NGS.
Table 2.
Gene mutation results obtained by cobas and NGS methods in 50 consecutive NSCLC patients referred for T790M resistance mutation analysis due to relapse after TKI treatment.
Fig 6.
NGS-cobas comparison in 50 EGFR mutant NSCLC patients in relapse following EGFR TKIs treatment.
EGFR sens.: EGFR sensitizing mutations in exons 18, 19, 21.
Fig 7.
Apportionment of the 59 NSCLC patients with at least one variant identified in liquid biopsy analysis, using 4 different biomarker categories: traditional targeted treatment biomarkers (EGFR, ALK); all approved treatment associated biomarkers (EGFR, ALK, BRAF); approved and emerging treatment biomarkers (EGFR, ALK, BRAF, HER2); approved, emerging treatment & clinical trials associated biomarkers (EGFR, ALK, BRAF, HER2, KRAS, NRAS, MET, PIK3CA, STK11,TP53).
In case a patient harbors more than one mutation the categorization is based on the more clinically significant variant.